The pharmacological point of view of resistance to therapy in tumors

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Resistance to therapy is a challenging clinical problem, whose solution is far from being reached. Gains in current knowledge have identified key elements at the basis of drug resistance and have suggested possible ways to overcome it. However, some points have always to be kept in mind whatever the type of tumor or drug (cytotoxic or targeted agent) when considering treatment resistance in tumors. In this review we discuss these points and their impact in resistance to cancer therapy: the importance of reaching active tumor drug concentration, reviewing the various micro- and macro-components of the host that can influence their concentrations and activity, the evolving complex heterogeneity of tumors, the intrinsic tumor cell susceptibility to the drug, and the emerging role of the tumor microenvironment. Both the data from the molecular and biological characterization of human tumors allow a better rational and timing use of the available arsenal of anticancer therapy and new strategies to improve the penetration of antitumor drugs in tumors are the new chances to delay and possibly eliminate the emergence of resistance in tumors.

Original languageEnglish
Pages (from-to)909-916
Number of pages8
JournalCancer Treatment Reviews
Volume40
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Pharmacology
Neoplasms
Therapeutics
Pharmaceutical Preparations
Tumor Microenvironment
Drug Resistance
Antineoplastic Agents

Keywords

  • Drug distribution
  • Resistance
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

The pharmacological point of view of resistance to therapy in tumors. / Damia, Giovanna; Garattini, Silvio.

In: Cancer Treatment Reviews, Vol. 40, No. 8, 2014, p. 909-916.

Research output: Contribution to journalArticle

@article{78cdd4adbb0d4d6180cf50f5088e78b1,
title = "The pharmacological point of view of resistance to therapy in tumors",
abstract = "Resistance to therapy is a challenging clinical problem, whose solution is far from being reached. Gains in current knowledge have identified key elements at the basis of drug resistance and have suggested possible ways to overcome it. However, some points have always to be kept in mind whatever the type of tumor or drug (cytotoxic or targeted agent) when considering treatment resistance in tumors. In this review we discuss these points and their impact in resistance to cancer therapy: the importance of reaching active tumor drug concentration, reviewing the various micro- and macro-components of the host that can influence their concentrations and activity, the evolving complex heterogeneity of tumors, the intrinsic tumor cell susceptibility to the drug, and the emerging role of the tumor microenvironment. Both the data from the molecular and biological characterization of human tumors allow a better rational and timing use of the available arsenal of anticancer therapy and new strategies to improve the penetration of antitumor drugs in tumors are the new chances to delay and possibly eliminate the emergence of resistance in tumors.",
keywords = "Drug distribution, Resistance, Tumor heterogeneity",
author = "Giovanna Damia and Silvio Garattini",
year = "2014",
doi = "10.1016/j.ctrv.2014.05.008",
language = "English",
volume = "40",
pages = "909--916",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - The pharmacological point of view of resistance to therapy in tumors

AU - Damia, Giovanna

AU - Garattini, Silvio

PY - 2014

Y1 - 2014

N2 - Resistance to therapy is a challenging clinical problem, whose solution is far from being reached. Gains in current knowledge have identified key elements at the basis of drug resistance and have suggested possible ways to overcome it. However, some points have always to be kept in mind whatever the type of tumor or drug (cytotoxic or targeted agent) when considering treatment resistance in tumors. In this review we discuss these points and their impact in resistance to cancer therapy: the importance of reaching active tumor drug concentration, reviewing the various micro- and macro-components of the host that can influence their concentrations and activity, the evolving complex heterogeneity of tumors, the intrinsic tumor cell susceptibility to the drug, and the emerging role of the tumor microenvironment. Both the data from the molecular and biological characterization of human tumors allow a better rational and timing use of the available arsenal of anticancer therapy and new strategies to improve the penetration of antitumor drugs in tumors are the new chances to delay and possibly eliminate the emergence of resistance in tumors.

AB - Resistance to therapy is a challenging clinical problem, whose solution is far from being reached. Gains in current knowledge have identified key elements at the basis of drug resistance and have suggested possible ways to overcome it. However, some points have always to be kept in mind whatever the type of tumor or drug (cytotoxic or targeted agent) when considering treatment resistance in tumors. In this review we discuss these points and their impact in resistance to cancer therapy: the importance of reaching active tumor drug concentration, reviewing the various micro- and macro-components of the host that can influence their concentrations and activity, the evolving complex heterogeneity of tumors, the intrinsic tumor cell susceptibility to the drug, and the emerging role of the tumor microenvironment. Both the data from the molecular and biological characterization of human tumors allow a better rational and timing use of the available arsenal of anticancer therapy and new strategies to improve the penetration of antitumor drugs in tumors are the new chances to delay and possibly eliminate the emergence of resistance in tumors.

KW - Drug distribution

KW - Resistance

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84904818154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904818154&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2014.05.008

DO - 10.1016/j.ctrv.2014.05.008

M3 - Article

VL - 40

SP - 909

EP - 916

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 8

ER -